Nuvation Bio Inc., a global oncology company, has announced that its innovative cancer treatment, taletrectinib, is currently under Priority Review by the U.S. Food and Drug Administration (FDA). This review is part of the ongoing regulatory process, with a Prescription Drug User Fee Act (PDUFA) date set for June 23, 2025. The drug, aimed at treating advanced ROS1-positive non-small cell lung cancer, has shown promising results in pivotal Phase 2 clinical studies, which will be presented at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting. Nuvation Bio is hopeful for a positive outcome, potentially providing a new, meaningful treatment option for patients affected by this disease.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。